Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical PracticeMalavika Deodhar, Véronique Michaud, Lucy I. Darakjian et al.|Pharmaceutics|2020Cited by 237
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with PolypharmacyJulie Doan, Cara Tannenbaum, Jacques Turgeon et al.|Annals of Pharmacotherapy|2013Cited by 186
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Étienne Lessard, Jacques Turgeon, Jacynthe LeBlanc et al.|PubMed|1999Cited by 177
Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility DisordersBenoît Drolet, Jacques Turgeon, René Cardinal et al.|Circulation|2000Cited by 164
Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT IntervalBenoît Drolet, Jacques Turgeon, Bettina A. Hamelin et al.|Circulation|1998Cited by 161